Humana Inc. (NYSE:HUM) Holdings Raised by South Dakota Investment Council

South Dakota Investment Council increased its stake in shares of Humana Inc. (NYSE:HUM - Free Report) by 39.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 153,317 shares of the insurance provider's stock after purchasing an additional 43,719 shares during the quarter. Humana makes up approximately 0.8% of South Dakota Investment Council's holdings, making the stock its 13th largest holding. South Dakota Investment Council owned 0.13% of Humana worth $38,898,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Creative Financial Designs Inc. ADV lifted its stake in shares of Humana by 244.0% during the third quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider's stock valued at $27,000 after buying an additional 61 shares during the period. Ashton Thomas Securities LLC acquired a new position in Humana in the 3rd quarter valued at $31,000. Your Advocates Ltd. LLP lifted its stake in shares of Humana by 81.8% during the 3rd quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider's stock worth $32,000 after purchasing an additional 45 shares during the period. FPC Investment Advisory Inc. purchased a new position in shares of Humana during the 4th quarter worth $27,000. Finally, Centricity Wealth Management LLC purchased a new stake in shares of Humana in the fourth quarter valued at $30,000. Hedge funds and other institutional investors own 92.38% of the company's stock.

Insider Activity

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the firm's stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the sale, the insider now owns 8,181 shares in the company, valued at approximately $2,096,463.06. This trade represents a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.32% of the company's stock.

Humana Stock Performance

Shares of NYSE HUM traded up $0.87 during midday trading on Monday, hitting $256.78. The company's stock had a trading volume of 896,157 shares, compared to its average volume of 1,682,340. Humana Inc. has a 1-year low of $213.31 and a 1-year high of $406.46. The firm's fifty day moving average price is $269.41 and its 200-day moving average price is $289.61. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76. The firm has a market cap of $30.98 billion, a P/E ratio of 25.82, a P/E/G ratio of 2.05 and a beta of 0.56.

Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. On average, sell-side analysts forecast that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be issued a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.38%. The ex-dividend date is Friday, March 28th. Humana's dividend payout ratio (DPR) is presently 35.58%.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on HUM shares. Truist Financial raised their price target on Humana from $260.00 to $290.00 and gave the stock a "hold" rating in a research note on Monday, January 6th. Cantor Fitzgerald reissued a "neutral" rating and issued a $290.00 target price on shares of Humana in a research report on Wednesday, February 12th. Barclays lifted their price target on shares of Humana from $255.00 to $270.00 and gave the company an "equal weight" rating in a report on Thursday, February 13th. Bank of America upgraded shares of Humana from an "underperform" rating to a "neutral" rating and lifted their price target for the company from $247.00 to $308.00 in a report on Wednesday, November 6th. Finally, TD Cowen raised their target price on shares of Humana from $261.00 to $268.00 and gave the company a "hold" rating in a research note on Monday, November 4th. Nineteen analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $285.68.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.